View Printer-Friendly PDF

A Drug Development & Outsourcing Profile

Actelion Pharmaceuticals Canada Inc.

300-3111 Saint-Martin Blvd. West
Laval QC  H7T 0K2
Canada

  • Tel: 450-681-1664
  • 866-531-4885
  • Fax: 450-681-9545
  • Dir: Mr. Reggie Downey
  • Mgmt: Mr. Reggie Downey
  • R&D: Ms. Marie-Claude Lefebvre
  • Licng:
  • Est: 2001 - Public
  • Rev: $ M
  • Staff: 10–50
  • Dermatology
  • Drug Development
  • Discovery Screening
  • Lead Optimizat'n
  • Contract Manufact.
  • Hypertension
  • Research & Dev.
  • Rx/Prescription

Affiliate of Actelion Ltd., a biopharmaceutical company, headquartered in Switzerland. Actelion's first drug Tracleer™, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer™ through subsidiaries in key markets worldwide. (RX&D)

Mfg:    Labs:

SWX: ATLN

0.0256